UPDATE: Ebola vaccine webinar series

Through expert presentations and facilitated discussion, participants will examine emerging data on cross-protection, advances in clinical development, and the practical challenges of vaccine deployment, providing timely context ahead of the October SAGE meeting on Ebola vaccines.

Save the date for the webinars below. More information on the programme and links to register will be coming soon!

Evidence of cross-protection against BDBV following vaccination against Zaire ebolavirus

Date: Wednesday, 16 September 2026

Register here

Programme

Chairs: Krutika Kuppalli (ESCMID Vaccines Subcommittee), Folake Olayinka (African CDC) and Martin Grobusch (University of Amsterdam)

• 14:00–14:05 Introduction 
• 14:05–14:15 Epidemiologic and outbreak overview 
  • Speaker: Boris Pavlin (WHO) 
• 14:15–14:35 Scientific evidence for cross-protection 
  • Speaker: Beth-Ann Griswold Coller (BGC Vaccine Consulting LLC Leader R&D Blueprint Filovirus RoadMap Vaccine Working Group)
• 14:35–14:50 WHO SAGE perspective 
  • Speaker: Annelies Wilder-Smith (WHO SAGE)
• 14:50–15:05 Evaluation of Ervebo: MSF perspective 
  • Speaker: Lise Denoeud (Epicentre, Geneva, Switzerland)
• 15:05–15:20 DRC Plans for evaluating Ervebo: Ministry of Health/Africa CDC perspective 
  • Speaker: Placide Mbala (Africa Centre for Disease Control)
• 15:20–15:30 Q&A

The BDBV vaccine development pipeline: from early development to phase 2/3 evaluation

Date: Wednesday, 30 September 2026

Register here

Programme

Chairs: Maheshi Ramasamy (ESCMID Vaccines Subcommittee) & Marta Mora-Rillo (ESCMID Emerging Infections Subcommittee)

• 14:15–14:20 Introduction 
• 14:20–14:30 The CEPI BDBV vaccine strategy
  • Speaker: Rachael Bonawitz (CEPI)
• 14:30–14:40 From crisis to preparedness: vaccine development during and between outbreaks - insights on BDBV
  • Speaker: Teresa Lambe (University of Oxford)
• 14:40–14:50 Operational & methodological considerations in the Tumaini Trial (Bundibugyo vaccine effectiveness trial)
  • Speaker: Jean-Pierre Van geertruyden (University of Antwerp)
• 14:50–15:00 Evidence to support advancement and regulatory approval for BDBV vaccines
  • Speaker: Marco Cavaleri (EMA)
• 15:00–15:30 Q&A

From licensure to impact: implementing BDBV vaccination programmes

Date: Wednesday, 14 October 2026

Registration: Coming soon